Authors: Hortobagyi, GN Ueno, NT Xia, WY Zhang, S Wolf, JK Putnam, JB Weiden, PL Willey, JS Carey, M Branham, DL Payne, JY Tucker, SD Bartholomeusz, C Kilbourn, RG De Jager, RL Sneige, N Katz, RL Anklesaria, P Ibrahim, NK Murray, JL Theriault, RL Valero, V Gershenson, DM Bevers, MW Huang, L Lopez-Berestein, G Hung, MC

Citation: Gn. Hortobagyi et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial, J CL ONCOL, 19(14), 2001, pp. 3422-3433

Authors: Rowinsky, EK Johnson, TR Geyer, CE Hammond, LA Eckhardt, SG Drengler, R Smetzer, L Coyle, J Rizzo, J Schwartz, G Tolcher, A Von Hoff, DD De Jager, RL

Citation: Ek. Rowinsky et al., DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies, J CL ONCOL, 18(17), 2000, pp. 3151-3163

Authors: Lawrence, RA Izbicka, E De Jager, RL Tohgo, A Clark, GM Weitman, SD Rowinsky, EK Von Hoff, DD

Citation: Ra. Lawrence et al., Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells, ANTI-CANC D, 10(7), 1999, pp. 655-661